The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
Subscribe To Our Newsletter & Stay Updated
